pharma · Chronic obstructive pulmonary disease (COPD) · Partial Epilepsy in Children and Adolescents
Bial Portela &
Bial Portela & Companhia S.A.
Bial Portela & clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- EU
- Programs
- 7
- Drugs
- 7
- Patents
- 3
Bial Portela & projects
5 ClinicalTrials.gov programs sponsored by Bial Portela &.
Bial Portela & has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
2019/ABM/01/00074
Bial Portela & Companhia S.A.
Chronic obstructive pulmonary disease (COPD)
1 trial -
2021/ABM/01/00010
Bial Portela & Companhia S.A.
Rare and ultra-rare glomerulonephritis
1 trial -
Eslicarbazepine acetate (BIA 2-093)
Bial Portela & Companhia S.A.
Partial Epilepsy in Children and Adolescents
1 trial -
GLUCOPHAGE 500 mg tabletki powlekane, Placebo
Bial Portela & Companhia S.A.
papillary thyroid carcinoma
1 trial -
PSMA-11 kit for Ga-68 labelling
Bial Portela & Companhia S.A.
Intermediate and high-risk prostate cancer
1 trial
Frequently asked questions
How many clinical projects does Bial Portela & have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.